Evidence map›Paper›PMID 35772465›Full record

ReviewThe Lancet. Oncology2022

2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19.

Dominique Farge, Corinne Frere, Jean M Connors, Alok A Khorana, Ajay Kakkar, Cihan Ay, Andres Muñoz, Benjamin Brenner, Pedro H Prata, Dialina Brilhante and 10 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The Lancet. Oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 235 papers, 17 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
235citing papers in PubMed, 17 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

235 citing papers in PubMed, 17 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. High IntratumoralInternational journal of molecular sciences · 2026
    Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Pooled it
  16. Pooled it
  17. Pooled it
  18. Trial
  19. Trial
  20. Article

175 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Dominique FargeUnité de Médecine Interne (UF04): CRMR MATHEC, Maladies Auto-immunes et Thérapie Cellulaire, Hôpital Saint-Louis, Assistance Publique Hôpitaux de Paris, Nord-Université de Paris, Paris, France; Faculté de Médecine, Institut de Recherche St-Louis, EA-3518, Université de Paris, Paris, France; Department of Medicine, Research Institute of the McGill University Health Centre, McGill University, Montreal, QC, Canada. Electronic address: itaccme@gmail.com.
Corinne FrereINSERM UMRS 1166, GRC 27 GRECO, DMU BioGeM, Assistance Publique Hôpitaux de Paris, Sorbonne University, Paris, France.
Jean M ConnorsHematology Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Alok A KhoranaTaussig Cancer Institute and Case Comprehensive Cancer Center, Cleveland Clinic, Cleveland, OH, USA.
Ajay KakkarThrombosis Research Institute, London, UK; Faculty of Medical Sciences, University College London, London, UK.
Cihan AyClinical Division of Hematology and Hemostaseology, Department of Medicine, Medical University of Vienna, Vienna, Austria.
Andres MuñozMedical Oncology Department, Hospital General Universitario Gregorio Marañón, Universidad Complutense, Madrid, Spain.
Benjamin BrennerDepartment of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel.
Pedro H PrataHematology-Transplantation Department, Hôpital Saint-Louis, Assistance Publique Hôpitaux de Paris, Nord-Université de Paris, Paris, France.
Dialina BrilhanteFrancisco Gentil Portuguese Institute of Oncology, Lisbon Center, Lisbon, Portugal.
Darko AnticClinic for Hematology, Clinical Center Serbia, University of Belgrade, Belgrade, Serbia.
Patricia CasaisInstituto de Investigaciones en Salud Pública, Universidad de Buenos, Buenos Aires, Argentina.
María Cecilia Guillermo EspositoDepartamento Clínico de Medicina, Manuel Quintela Clinic Hospital, Montevideo, Uruguay.
Takayuki IkezoeDepartment of Hematology, Fukushima Medical University, Fukushima, Japan.
Syed A AbutalibCancer Treatment Centers of America, Chicago, IL, USA.
Luis A Meillon-GarcíaThe ABC Medical Center, Mexico City, Mexico.
Henri BounameauxFaculty of Medicine, University of Geneva, Geneva, Switzerland.
Ingrid PabingerClinical Division of Hematology and Hemostaseology, Department of Medicine, Medical University of Vienna, Vienna, Austria.
James DouketisDepartment of Medicine, McMaster University, Hamilton, ON, Canada.
International Initiative on Thrombosis and Cancer (ITAC) advisory panel

Funding

Novel approaches to improve prediction of cancer-associated thrombosisU01HL143402 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI KHORANA, ALOK A, MCCRAE, KEITH R. · 2018 to 2022
$4.7M
NHLBI NIH HHS U01 HL143402
6 · The paper itself

Abstract

The International Initiative on Thrombosis and Cancer is an independent academic working group of experts aimed at establishing global consensus for the treatment and prophylaxis of cancer-associated thrombosis. The 2013, 2016, and 2019 International Initiative on Thrombosis and Cancer clinical practice guidelines have been made available through a free, web-based mobile phone application. The 2022 clinical practice guidelines, which are based on a literature review up to Jan 1, 2022, include guidance for patients with cancer and with COVID-19. Key recommendations (grade 1A or 1B) include: (1) low-molecular-weight heparins (LMWHs) for the initial (first 10 days) treatment and maintenance treatment of cancer-associated thrombosis; (2) direct oral anticoagulants for the initial treatment and maintenance treatment of cancer-associated thrombosis in patients who are not at high risk of gastrointestinal or genitourinary bleeding, in the absence of strong drug-drug interactions or of gastrointestinal absorption impairment; (3) LMWHs or direct oral anticoagulants for a minimum of 6 months to treat cancer-associated thrombosis; (4) extended prophylaxis (4 weeks) with LMWHs to prevent postoperative venous thromboembolism after major abdominopelvic surgery in patients not at high risk of bleeding; and (5) primary prophylaxis of venous thromboembolism with LMWHs or direct oral anticoagulants (rivaroxaban or apixaban) in ambulatory patients with locally advanced or metastatic pancreatic cancer who are treated with anticancer therapy and have a low risk of bleeding.

Indexed as

COVID-19NeoplasmsThrombosisVenous ThromboembolismAnticoagulantsHemorrhageHeparin, Low-Molecular-WeightHumansPractice Guidelines as TopicAnticoagulantsHeparin, Low-Molecular-Weight

Identifiers

PMID35772465
PMCPMC9236567

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.